gefitinib has been researched along with oleanolic acid in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (oleanolic acid) | Trials (oleanolic acid) | Recent Studies (post-2010) (oleanolic acid) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 4,169 | 31 | 2,404 |
| Protein | Taxonomy | gefitinib (IC50) | oleanolic acid (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 2.045 | |
| Phospholipase A2 | Homo sapiens (human) | 3 | |
| DNA polymerase beta | Homo sapiens (human) | 6.8667 | |
| DNA polymerase beta | Rattus norvegicus (Norway rat) | 5.6 | |
| Receptor-type tyrosine-protein phosphatase C | Homo sapiens (human) | 1 | |
| Receptor-type tyrosine-protein phosphatase F | Homo sapiens (human) | 3.065 | |
| Tissue factor | Homo sapiens (human) | 0.005 | |
| Tyrosine-protein phosphatase non-receptor type 2 | Homo sapiens (human) | 4.38 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 2.8444 | |
| Liver carboxylesterase 1 | Homo sapiens (human) | 0.1 | |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | 3.065 | |
| M-phase inducer phosphatase 2 | Homo sapiens (human) | 0.98 | |
| Dual specificity protein phosphatase 3 | Homo sapiens (human) | 5.4 | |
| Transcription factor p65 | Homo sapiens (human) | 2.4 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 3.065 | |
| Protease | Human immunodeficiency virus 1 | 8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, B; Hou, XY; Shi, JJ; Zhang, CL; Zhao, CH; Zhao, LX | 1 |
| Chen, Z; Cheng, YY; Duan, HQ; Goto, M; Huang, KY; Lee, KH; Ling, Y; Liu, YL; Morris-Natschke, SL; Tong, XH; Yang, PC; Yang, SL | 1 |
| Kuai, ZY; Li, W; Liu, LW; Meng, YQ; Zhao, YW | 1 |
3 other study(ies) available for gefitinib and oleanolic acid
| Article | Year |
|---|---|
Design, synthesis, and biofunctional evaluation of novel pentacyclic triterpenes bearing O-[4-(1-piperazinyl)-4-oxo-butyryl moiety as antiproliferative agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pentacyclic Triterpenes; Piperazines; Structure-Activity Relationship | 2015 |
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
Topics: A549 Cells; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Nitric Oxide; Nitric Oxide Donors; Oleanolic Acid; Protein Kinase Inhibitors | 2019 |
Synthesis and antitumor activity evaluation of novel oleanolic acid derivatives.
Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Gefitinib; HeLa Cells; Humans; Molecular Docking Simulation; Molecular Structure; Oleanolic Acid; Pentacyclic Triterpenes; Proto-Oncogene Proteins c-kit; Quinazolines; Structure-Activity Relationship | 2017 |